Literature DB >> 26069105

Polymorphisms of FGFR1 in HBV-related hepatocellular carcinoma.

Haiyang Xie1, Chunyang Xing1, Bajin Wei1, Xiao Xu1, Liming Wu1, Jian Wu1, Leiming Chen1, Guoqiang Cao1, Hai Chen1, Xueqin Meng1, Shengyong Yin1, Lin Zhou1, Shusen Zheng2.   

Abstract

Hepatitis B virus (HBV)-induced hepatocellular carcinoma (HCC) is one of the most commonly diagnosed cancers in China. It is important to understand the genetic mechanisms underlying the development and progression of HBV-related HCC and to identify new biomarkers for clinical treatment. The important role of fibroblast growth factor receptors (FGFRs) has been widely recognized in many types of cancers, but the association between FGFR polymorphisms and HCC carcinogenesis has been rarely reported. In this study, 199 patients with HBV-associated cirrhosis, 203 with HBV-associated HCC, and 184 healthy controls with no liver diseases were enrolled as participants. Using SNaPshot assays, five SNPs (rs13317, rs7825208, rs1047057, rs1047111, and rs1966265) of growth factor receptor genes were genotyped. Our results showed that the G/A and G/G genotypes at rs7825208 of FGFR1 were negatively correlated with HBV-related HCC (odds ratio (OR) = 0.45, 95% confidence interval (CI) = 0.22-0.93, P = 0.027). However, after Bonferroni correction, these significant differences no longer existed (P > 0.05). Our results indicated that these five polymorphisms of fibroblast growth factor receptor genes do not play any independent roles in the tumorigenesis and progression of HBV-related HCC in Han Chinese patients.

Entities:  

Keywords:  FGFR1; HBV; HCC; Liver cirrhosis; Polymorphism

Mesh:

Substances:

Year:  2015        PMID: 26069105     DOI: 10.1007/s13277-015-3643-4

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  34 in total

1.  Polymorphism in 3'-untranslated region of toll-like receptor 4 gene is associated with protection from hepatitis B virus recurrence after liver transplantation.

Authors:  L Zhou; B Wei; C Xing; H Xie; X Yu; L Wu; S Zheng
Journal:  Transpl Infect Dis       Date:  2010-10-26       Impact factor: 2.228

Review 2.  Mechanisms underlying differential responses to FGF signaling.

Authors:  Lisa Dailey; Davide Ambrosetti; Alka Mansukhani; Claudio Basilico
Journal:  Cytokine Growth Factor Rev       Date:  2005-03-05       Impact factor: 7.638

3.  Liver Cancer Working Group report.

Authors:  Masatoshi Kudo; Kwang Hyub Han; Norihiro Kokudo; Ann-Lii Cheng; Byung Ihn Choi; Junji Furuse; Namiki Izumi; Joong-Won Park; Ronnie T Poon; Michiie Sakamoto
Journal:  Jpn J Clin Oncol       Date:  2010-09       Impact factor: 3.019

Review 4.  Isoforms of receptors of fibroblast growth factors.

Authors:  Siew-Ging Gong
Journal:  J Cell Physiol       Date:  2014-12       Impact factor: 6.384

Review 5.  Cellular signaling by fibroblast growth factor receptors.

Authors:  V P Eswarakumar; I Lax; J Schlessinger
Journal:  Cytokine Growth Factor Rev       Date:  2005-02-01       Impact factor: 7.638

Review 6.  HCC and angiogenesis: possible targets and future directions.

Authors:  Andrew X Zhu; Dan G Duda; Dushyant V Sahani; Rakesh K Jain
Journal:  Nat Rev Clin Oncol       Date:  2011-03-08       Impact factor: 66.675

Review 7.  Cell responses to FGFR3 signalling: growth, differentiation and apoptosis.

Authors:  Corine G M L'Hôte; Margaret A Knowles
Journal:  Exp Cell Res       Date:  2004-12-16       Impact factor: 3.905

8.  AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor.

Authors:  Masayuki Takeda; Tokuzo Arao; Hideyuki Yokote; Teruo Komatsu; Kazuyoshi Yanagihara; Hiroki Sasaki; Yasuhide Yamada; Tomohide Tamura; Kazuya Fukuoka; Hiroshi Kimura; Nagahiro Saijo; Kazuto Nishio
Journal:  Clin Cancer Res       Date:  2007-05-15       Impact factor: 12.531

9.  Clinical and biological characteristics of cervical neoplasias with FGFR3 mutation.

Authors:  Christophe Rosty; Marie-Hélène Aubriot; David Cappellen; Jérôme Bourdin; Isabelle Cartier; Jean Paul Thiery; Xavier Sastre-Garau; François Radvanyi
Journal:  Mol Cancer       Date:  2005-05-03       Impact factor: 27.401

10.  Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis.

Authors:  Bi-Sen Ding; Zhongwei Cao; Raphael Lis; Daniel J Nolan; Peipei Guo; Michael Simons; Mark E Penfold; Koji Shido; Sina Y Rabbany; Shahin Rafii
Journal:  Nature       Date:  2013-11-20       Impact factor: 49.962

View more
  1 in total

Review 1.  Advances of Fibroblast Growth Factor/Receptor Signaling Pathway in Hepatocellular Carcinoma and its Pharmacotherapeutic Targets.

Authors:  Haijun Wang; Jie Yang; Ke Zhang; Jia Liu; Yushan Li; Wei Su; Na Song
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.